Sanofi says Gaucher pill studies meet goals

PARIS Fri Feb 15, 2013 10:44pm IST

Chris Viehbacher, Chief Executive Officer of Sanofi, poses for the media before the company's 2012 annual results presentation in Paris February 7, 2013. REUTERS/Jacky Naegelen

Chris Viehbacher, Chief Executive Officer of Sanofi, poses for the media before the company's 2012 annual results presentation in Paris February 7, 2013.

Credit: Reuters/Jacky Naegelen

Related Topics

Stocks

   

PARIS (Reuters) - Sanofi said its experimental pill for Gaucher disease met its main targets in two late-stage studies, which the French drugmaker will use to bolster its case for regulatory approval.

Eliglustat tartrate could become the first oral treatment for Gaucher disease - a rare genetic disorder affecting some 10,000 patients - and shake up the market for therapies that currently have to be injected bi-weekly.

Eliglustat could generate annual sales of $360 million by 2017, according to ThomsonReuters Pharma forecasts.

Patients with Gaucher disease are deficient in an enzyme that breaks down a certain type of fat, leading to potentially life-threatening organ damage and bone problems.

The first study, presented at a medical congress on Friday, compared eliglustat with a placebo, while the second compared it with Cerezyme, an injectable treatment also sold by Sanofi.

Patients treated with the pill showed a "statistically significant improvement" in the size of their spleen - which typically swells as a result of Gaucher disease - without reporting serious side effects, Sanofi said.

Eliglustat also proved to be as good as Cerezyme at treating the symptoms of the disease, the drugmaker added.

Full data from the second trial will be presented at a medical meeting in the second half of 2013, Sanofi said in a statement.

A third late-stage study is currently testing whether the dosage for eliglustat could be reduced to once from twice daily.

In addition to Cerezyme, which for many years dominated the Gaucher market and was at one point the most expensive drug in the world, costing more than $200,000 a year, current treatments include Shire's Vpriv and Elelyso, sold by Pfizer.

(Reporting by Elena Berton; Editing by Christian Plumb and James Regan)

FILED UNDER:

Fighting Ebola

REUTERS SHOWCASE

SpiceJet Bail-Out

SpiceJet Bail-Out

Co-founder of SpiceJet seeks time to finalise rescue  Full Article 

Regulating Airfares

Regulating Airfares

India considers temporary cap on airfares - government official  Full Article 

Ten Years On

Ten Years On

British tsunami brothers use funky footwear to help children.  Full Article 

Fund Raising

Fund Raising

Xiaomi raising over $1 bln from investors including GIC - source.  Full Article 

Porn Crackdown

Porn Crackdown

China arrests thousands in porn, gambling crackdown - Xinhua.  Full Article 

India v Australia

India v Australia

Boxing Day test of India's resolve in Melbourne.  Full Article | Related Story 

Jaycee Charged

Jaycee Charged

China charges Jackie Chan's son over drug offence.  Full Article 

China on Cyberattacks

China on Cyberattacks

China condemns cyberattacks, but does not mention North Korea.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device   Full Coverage